Loading…

RiPP antibiotics: biosynthesis and engineering potential

[Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in e...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in microbiology 2018-10, Vol.45 (C), p.61-69
Main Authors: Hudson, Graham A, Mitchell, Douglas A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3
cites cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3
container_end_page 69
container_issue C
container_start_page 61
container_title Current opinion in microbiology
container_volume 45
creator Hudson, Graham A
Mitchell, Douglas A
description [Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.
doi_str_mv 10.1016/j.mib.2018.02.010
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6131089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1369527417300826</els_id><sourcerecordid>2013786884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</originalsourceid><addsrcrecordid>eNp9UdFKHDEUDcVSrfYD-iKLT32ZMZlkZhIFoYitglCR9jlkkju7d5lNtkl2wb83y1qpLz6EXLjnnHvuPYR8ZbRmlHXny3qFQ91QJmva1JTRD-SIyV5VlHfioNS8U1Xb9OKQfE5pSSkVqu0-kcNGtZxL0R4R-YgPDzPjMw4YMtp0MStFevJ5AQlT6bgZ-Dl6gIh-PluHDAVsphPycTRTgi8v_zH58-Pm9_Vtdf_r59319_vKtkLkSva2kbxRTnKwdOxHKN6Ms60dx1Y5pQYwXV-e4K1xfT9w5vhgJLemAaCWH5Orve56M6zA2TI9mkmvI65MfNLBoH7b8bjQ87DVHeOMSlUEzvYCIWXUyWIGu7DBe7BZs04JxmQBfXuZEsPfDaSsV5gsTJPxEDZJlxvzXnZSigJle6iNIaUI46sXRvUuFr0s5GFHkZo2usRSOKf_L_HK-JdDAVzuAVBOuUWIO6PgLTiMO58u4Dvyzwj8nvo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013786884</pqid></control><display><type>article</type><title>RiPP antibiotics: biosynthesis and engineering potential</title><source>Elsevier</source><creator>Hudson, Graham A ; Mitchell, Douglas A</creator><creatorcontrib>Hudson, Graham A ; Mitchell, Douglas A</creatorcontrib><description>[Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</description><identifier>ISSN: 1369-5274</identifier><identifier>EISSN: 1879-0364</identifier><identifier>DOI: 10.1016/j.mib.2018.02.010</identifier><identifier>PMID: 29533845</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - metabolism ; Anti-Bacterial Agents - pharmacology ; Bacteria - drug effects ; Bacteria - genetics ; Bacteria - metabolism ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Biosynthetic Pathways ; Humans ; Peptides - chemistry ; Peptides - metabolism ; Peptides - pharmacology ; Protein Processing, Post-Translational ; Ribosomes - genetics ; Ribosomes - metabolism</subject><ispartof>Current opinion in microbiology, 2018-10, Vol.45 (C), p.61-69</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</citedby><cites>FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</cites><orcidid>0000-0002-9564-0953 ; 0000000295640953</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29533845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/1694118$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Hudson, Graham A</creatorcontrib><creatorcontrib>Mitchell, Douglas A</creatorcontrib><title>RiPP antibiotics: biosynthesis and engineering potential</title><title>Current opinion in microbiology</title><addtitle>Curr Opin Microbiol</addtitle><description>[Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</description><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - metabolism</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - genetics</subject><subject>Bacteria - metabolism</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Biosynthetic Pathways</subject><subject>Humans</subject><subject>Peptides - chemistry</subject><subject>Peptides - metabolism</subject><subject>Peptides - pharmacology</subject><subject>Protein Processing, Post-Translational</subject><subject>Ribosomes - genetics</subject><subject>Ribosomes - metabolism</subject><issn>1369-5274</issn><issn>1879-0364</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UdFKHDEUDcVSrfYD-iKLT32ZMZlkZhIFoYitglCR9jlkkju7d5lNtkl2wb83y1qpLz6EXLjnnHvuPYR8ZbRmlHXny3qFQ91QJmva1JTRD-SIyV5VlHfioNS8U1Xb9OKQfE5pSSkVqu0-kcNGtZxL0R4R-YgPDzPjMw4YMtp0MStFevJ5AQlT6bgZ-Dl6gIh-PluHDAVsphPycTRTgi8v_zH58-Pm9_Vtdf_r59319_vKtkLkSva2kbxRTnKwdOxHKN6Ms60dx1Y5pQYwXV-e4K1xfT9w5vhgJLemAaCWH5Orve56M6zA2TI9mkmvI65MfNLBoH7b8bjQ87DVHeOMSlUEzvYCIWXUyWIGu7DBe7BZs04JxmQBfXuZEsPfDaSsV5gsTJPxEDZJlxvzXnZSigJle6iNIaUI46sXRvUuFr0s5GFHkZo2usRSOKf_L_HK-JdDAVzuAVBOuUWIO6PgLTiMO58u4Dvyzwj8nvo</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Hudson, Graham A</creator><creator>Mitchell, Douglas A</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9564-0953</orcidid><orcidid>https://orcid.org/0000000295640953</orcidid></search><sort><creationdate>20181001</creationdate><title>RiPP antibiotics: biosynthesis and engineering potential</title><author>Hudson, Graham A ; Mitchell, Douglas A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - metabolism</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - genetics</topic><topic>Bacteria - metabolism</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Biosynthetic Pathways</topic><topic>Humans</topic><topic>Peptides - chemistry</topic><topic>Peptides - metabolism</topic><topic>Peptides - pharmacology</topic><topic>Protein Processing, Post-Translational</topic><topic>Ribosomes - genetics</topic><topic>Ribosomes - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hudson, Graham A</creatorcontrib><creatorcontrib>Mitchell, Douglas A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hudson, Graham A</au><au>Mitchell, Douglas A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RiPP antibiotics: biosynthesis and engineering potential</atitle><jtitle>Current opinion in microbiology</jtitle><addtitle>Curr Opin Microbiol</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>45</volume><issue>C</issue><spage>61</spage><epage>69</epage><pages>61-69</pages><issn>1369-5274</issn><eissn>1879-0364</eissn><abstract>[Display omitted] The threat of antibiotic resistant bacterial infections continues to underscore the need for new treatment options. Historically, small molecule metabolites from microbes have provided a rich source of antibiotic compounds, and as a result, significant effort has been invested in engineering the responsible biosynthetic pathways to generate novel analogs with attractive pharmacological properties. Unfortunately, biosynthetic stringency has limited the capacity of non-ribosomal peptide synthetases and polyketide synthases from producing substantially different analogs in large numbers. Another class of natural products, the ribosomally synthesized and post-translationally modified peptides (RiPPs), have rapidly expanded in recent years with many natively displaying potent antibiotic activity. RiPP biosynthetic pathways are modular and intrinsically tolerant to alternative substrates. Several prominent RiPPs with antibiotic activity will be covered in this review with a focus on their biosynthetic plasticity. While only a few RiPP enzymes have been thoroughly investigated mechanistically, this knowledge has already been harnessed to generate new-to-nature compounds. Through the use of synthetic biology approaches, on-going efforts in RiPP engineering hold great promise in unlocking the potential of this natural product class.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29533845</pmid><doi>10.1016/j.mib.2018.02.010</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9564-0953</orcidid><orcidid>https://orcid.org/0000000295640953</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1369-5274
ispartof Current opinion in microbiology, 2018-10, Vol.45 (C), p.61-69
issn 1369-5274
1879-0364
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6131089
source Elsevier
subjects Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - metabolism
Anti-Bacterial Agents - pharmacology
Bacteria - drug effects
Bacteria - genetics
Bacteria - metabolism
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Biosynthetic Pathways
Humans
Peptides - chemistry
Peptides - metabolism
Peptides - pharmacology
Protein Processing, Post-Translational
Ribosomes - genetics
Ribosomes - metabolism
title RiPP antibiotics: biosynthesis and engineering potential
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RiPP%20antibiotics:%20biosynthesis%20and%20engineering%20potential&rft.jtitle=Current%20opinion%20in%20microbiology&rft.au=Hudson,%20Graham%20A&rft.date=2018-10-01&rft.volume=45&rft.issue=C&rft.spage=61&rft.epage=69&rft.pages=61-69&rft.issn=1369-5274&rft.eissn=1879-0364&rft_id=info:doi/10.1016/j.mib.2018.02.010&rft_dat=%3Cproquest_pubme%3E2013786884%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-87c28329d83ec0f7fe036adc5cff59d99bea67ea6435ad77b31d3ba83ca2ee0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2013786884&rft_id=info:pmid/29533845&rfr_iscdi=true